Valeant Pharmaceuticals International, Inc. (NYSE:VRX) currently has an A verage Broker Rating of 3. This number is based on the 11 sell-side firms polled by Zacks. The ABR rank within the industry stands at 21. Analysts on a consensus basis are expecting that the stock will reach $16.92 within the year. The ABR is provided by Zacks which simplfies analyst ratings into an integer based number. They use a one to five scale where they translate brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 represents a consensus Sell rating.
An evaluation of a stock’s expected performance and/or its risk level as judged by a rating agency such as Standard and Poor’s. A stock rating will usually tell the investor how well a stock’s market value relates to what analysts believe is a fair value for the stock, based on an objective evaluation of the company. The greater the amount by which the fair value exceeds the market value, the more highly recommended a buy the stock is. Conversely, if the market value of the stock exceeds the fair value of the stock, then analysts recommend that the stock be sold.
Investors might be searching high and low for the next great stock to trade. Professional investors may have their game plans honed and ready to roll, but amateurs may be fighting to stay above water in the markets. Leaping into the equity markets without any preparation may lead to quick losses. Keeping track of all the ins and outs of daily market activity can be exhausting, and investors may be best served if they are able to focus on the essentials and rise above the noise. Although successful trading might be measured differently from one person to another, the general principles of winners are generally the same. Snatching profits from the market may seem like an easy task when stocks are soaring, but things can always snap back in the blink of an eye. Investors who are able to prepare for any situation may find themselves ahead of the game when the inevitable bear market scenario rears its head.
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) closed the last session at $11.41 and sees an average of 10072074 shares trade hands in each session. The 52-week low of the stock stands at $8.51 while the current level stands at 18.89% of the 52-week High-Low range. Looking further out we can see that the stock has moved -26.15% over the past 12 weeks and -21.42% year to date.
Research analysts are predicting that Valeant Pharmaceuticals International, Inc. (NYSE:VRX) will report earnings of $0.94 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.
Most recently Valeant Pharmaceuticals International, Inc. (NYSE:VRX) posted quarterly earnings of $1.05 which compared to the sell-side estimates of 0.91. The stock’s 12-month trailing earnings per share stands at $6.66. Shares have moved $-17.08 over the past month and more recently, $-8.57 over the past week heading into the earnings announcement. There are 7 analyst projections that were taken into consideration from respected brokerage firms.
3 analysts rate Valeant Pharmaceuticals International, Inc. a Buy or Strong Buy, which is 27.27% of all the analyst ratings.
When it comes to setting up a winning stock portfolio, many investors will select a wide variety of securities in order to minimize risk. This may include choosing a mix of small cap, large cap, value, and growth stocks. Many investors will also include foreign stocks in the portfolio as well. Once the portfolio is set up, investors may realize that they need to rebalance from time to time. Investors may find it extremely helpful to stay up to date and know exactly what holdings they have. When hard earned investing dollars are at stake, individuals may be best served to monitor the portfolio closely at all times. Putting in the extra time and effort to acquire stock market knowledge may help the investor become better prepared for the long haul.
This article is informational purposes only and should not be considered a recommendation to buy or sell the stock.